Kura Oncology (KURA)

$7.26 +0.08 (1.11%)
Market Cap 558.35M
Revenue (ttm) 0.00
Net Income (ttm) -152.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.02
Volume 1,174,500
Avg Vol 2,028,648
Day's Range N/A - N/A
Shares Out 77.76M
Stochastic %K 14%
Beta 0.81
Analysts Strong Sell
Price Target $28.50

Latest News on KURA

Kura Oncology Announces Senior Executive Promotions

Jan 6, 2025, 4:30 PM EST - 11 days ago

Kura Oncology Announces Senior Executive Promotions

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Dec 18, 2024, 1:46 PM EST - 4 weeks ago

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Dec 9, 2024, 7:00 AM EST - 5 weeks ago

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Dec 2, 2024, 7:30 AM EST - 6 weeks ago

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Nov 25, 2024, 7:30 AM EST - 7 weeks ago

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Nov 20, 2024, 5:52 PM EST - 2 months ago

Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Nov 20, 2024, 5:00 PM EST - 2 months ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 5:54 AM EST - 2 months ago

Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Nov 5, 2024, 9:09 AM EST - 2 months ago

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

Kura Oncology to Report Third Quarter 2024 Financial Results

Oct 31, 2024, 7:30 AM EDT - 2 months ago

Kura Oncology to Report Third Quarter 2024 Financial Results

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Oct 29, 2024, 8:00 AM EDT - 2 months ago

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Oct 24, 2024, 7:30 AM EDT - 3 months ago

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Oct 23, 2024, 7:30 AM EDT - 3 months ago

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Sep 30, 2024, 6:30 PM EDT - 3 months ago

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Sep 17, 2024, 7:30 AM EDT - 4 months ago

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 2:07 PM EDT - 5 months ago

Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

Aug 8, 2024, 7:30 AM EDT - 5 months ago

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

Kura Oncology to Report Second Quarter 2024 Financial Results

Aug 1, 2024, 7:30 AM EDT - 6 months ago

Kura Oncology to Report Second Quarter 2024 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 5, 2024, 7:30 AM EDT - 7 months ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

Jun 24, 2024, 7:30 AM EDT - 7 months ago

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community

Jun 11, 2024, 2:00 PM EDT - 7 months ago

Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community

Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 8 months ago

Kura Oncology to Participate in Jefferies Global Healthcare Conference

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 14, 2024, 7:30 AM EDT - 8 months ago

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 8, 2024, 7:30 AM EDT - 9 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript

May 4, 2024, 5:28 PM EDT - 9 months ago

Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript

Kura Oncology Reports First Quarter 2024 Financial Results

May 2, 2024, 4:05 PM EDT - 9 months ago

Kura Oncology Reports First Quarter 2024 Financial Results

Kura Oncology to Report First Quarter 2024 Financial Results

Apr 25, 2024, 7:30 AM EDT - 9 months ago

Kura Oncology to Report First Quarter 2024 Financial Results

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Apr 22, 2024, 7:30 AM EDT - 9 months ago

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Apr 10, 2024, 7:30 AM EDT - 10 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Mar 6, 2024, 7:30 AM EST - 11 months ago

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 10:19 PM EST - 11 months ago

Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 11 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Feb 26, 2024, 7:30 AM EST - 11 months ago

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology to Participate in Three Upcoming Investor Conferences

Feb 22, 2024, 7:30 AM EST - 11 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:30 AM EST - 11 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

Kura Oncology stock jumped another 20% on Tuesday: here's why

Jan 30, 2024, 8:41 AM EST - 1 year ago

Kura Oncology stock jumped another 20% on Tuesday: here's why

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Jan 30, 2024, 7:00 AM EST - 1 year ago

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Kura Oncology Announces Oversubscribed $150 Million Private Placement

Jan 24, 2024, 7:00 AM EST - 1 year ago

Kura Oncology Announces Oversubscribed $150 Million Private Placement

Kura Oncology: Riding The Menin Hype Wave In AML Therapy

Dec 12, 2023, 3:32 PM EST - 1 year ago

Kura Oncology: Riding The Menin Hype Wave In AML Therapy

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Dec 8, 2023, 7:30 AM EST - 1 year ago

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 7:30 AM EST - 1 year ago

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 4:12 PM EDT - 1 year ago

Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript

Kura Oncology Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 4:01 PM EDT - 1 year ago

Kura Oncology Reports Third Quarter 2023 Financial Results

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

Kura Oncology to Participate in Three Upcoming Investor Conferences

Oct 30, 2023, 7:30 AM EDT - 1 year ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology to Report Third Quarter 2023 Financial Results

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Kura Oncology to Report Third Quarter 2023 Financial Results

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Oct 19, 2023, 7:30 AM EDT - 1 year ago

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

Oct 17, 2023, 4:05 PM EDT - 1 year ago

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 4, 2023, 7:30 AM EDT - 1 year ago

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

Sep 28, 2023, 7:30 AM EDT - 1 year ago

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer